Can we safely stop TKI therapies? Experience from the STOP trials
Delphine Rea, Hôpital Saint-Louis, Paris, France
Please wait as the educational presentation will start automatically. You can also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.
|
|
Issues covered
- Unmet medical needs in currently available CML treatments
- Treatment options for CML with T315I mutation
- Treatment options after TKI intolerance
- Trial results with bosutinib, ponatinib, omacetaxine
- Results from studies investigating imatinib + interferon
|
Has this been helpful? Please provide your comments here:
Facteur de variabilité de la réponse au ITK</li>
<li>Les trois grand mécanismes de résistance</li>
<li>La réponse au traitement</li>
<li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib